RT Journal Article
SR Electronic
T1 Transcatheter aortic valve replacement and standard therapy in inoperable patients with aortic stenosis and low EF
JF Heart
JO Heart
FD BMJ Publishing Group Ltd and British Cardiovascular Society
SP 463
OP 471
DO 10.1136/heartjnl-2014-306737
VO 101
IS 6
A1 Jonathan J Passeri
A1 Sammy Elmariah
A1 Ke Xu
A1 Ignacio Inglessis
A1 Joshua N Baker
A1 Maria Alu
A1 Susheel Kodali
A1 Martin B Leon
A1 Lars G Svensson
A1 Philippe Pibarot
A1 William F Fearon
A1 Ajay J Kirtane
A1 Gus J Vlahakes
A1 Igor F Palacios
A1 Pamela S Douglas
A1 on behalf of the PARTNER Investigators
YR 2015
UL http://heart.bmj.com/content/101/6/463.abstract
AB Objectives The aims of this study were to evaluate the effect of left ventricular (LV) dysfunction on clinical outcomes after transcatheter aortic valve replacement (TAVR) and standard therapy for severe aortic stenosis (AS) and to assess LV ejection fraction (LVEF) recovery and its impact on subsequent clinical outcomes. Methods Cohort B of the Placement of AoRtic TraNscathetER Valves trial randomised 342 inoperable patients with severe AS to TAVR or standard therapy. We defined LV dysfunction as an LVEF <50% and LVEF improvement as an absolute increase in LVEF ≥10% at 30 days. Results Baseline LV dysfunction did not affect survival after TAVR but was associated with increased cardiac mortality at 1 year with standard therapy (59.3% vs 45.8% with normal LVEF; HR=1.71 (95% CI 1.08 to 2.71); p=0.02). In those with LV dysfunction, LVEF improvement occurred in 48.7% and 30.4% of TAVR and standard therapy patients, respectively (p=0.08), and was independently predicted by relative wall thickness and receipt of TAVR. LVEF improvement with standard therapy portended reduced all-cause mortality at 1 year (28.6% vs 65.6% without LVEF improvement; HR=0.32 (95% CI 0.11 to 0.93); p=0.03) but not at 2 years. Conclusions In inoperable patients with severe AS, mild-to-moderate LV dysfunction is associated with higher cardiac mortality with standard therapy but not TAVR. A subset of patients undergoing standard therapy with LV dysfunction demonstrates LVEF improvement and favourable 1-year but not 2-year survival. TAVR improves survival and should be considered the standard of care for inoperable patients with AS and LVEF >20%. Trial registration number ClinicalTrials.gov Unique Identifier #NCT00530894.